Pulmotype | Antibody immunohistochemistry test


Squamous	Adenocarcinoma	Adenocarcinoma with EGFR Mutation
Pulmotype^®Overview Pulmotype is a five antibody immunohistochemistry (IHC) test that can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer (NSCLC) tumor specimens. The histologic classification of NSCLC has gained clinical importance because current targeted therapies show different clinical potency or toxicity dependent upon the histotype of the tumor. Currently, there is no widely accepted standard to differentiate between NSCLC sub-types. Pulmotype was developed by screening candidate markers on 551 surgical specimens from a retrospective lung carcinoma cohort assembled at a regional US hospital. It was subsequently validated on three independent cohorts comprising over 1,100 NSCLC cases total. Pulmotype plays an important role in NSCLC diagnosis by complementing the morphological assessment already performed by pathologists when sufficient specimen is available, or by replacing morphologic assessment when the specimen is too sparse for morphologic interpretation. The use of Pulmotype for classification of NSCLC will lead to a more definitive diagnosis and better therapy decisions.